RxDoctor Payments Data

Ronald Caronia, MD

Ophthalmology · Oceanside, NYNPI 1720082118

Payments from drug & device makers

$51,011in general payments, 2019–2025

Across 199 payments — averaging $256.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$49K
  • Glaukos Corporation$382
  • Sun Pharmaceutical Industries Inc.$316
  • Novartis$283
  • Tarsus Pharmaceuticals, Inc.$264
  • Mallinckrodt Hospital Products Inc.$210
  • plus $849 from 14 others

What the payments were for

  • Food & beverage$2,98797%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,011 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$510,754
Medicare patients
965
Services billed
4,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine219$313,248
LumiganBimatoprost190$117,503
RhopressaNetarsudil Mesylate183$92,913
CombiganBrimonidine Tartrate/Timolol128$56,538
SimbrinzaBrinzolamide/Brimonidine Tart155$50,768
Timolol Maleate571$46,504
RocklatanNetarsudil Mesylat/Latanoprost60$43,963
Phospholine IodideEchothiophate Iodide16$41,906
Alphagan PBrimonidine Tartrate76$32,055
Cyclosporine61$31,639
Brimonidine Tartrate347$30,713
Travoprost126$30,669
XiidraLifitegrast14$25,024
ProlensaBromfenac Sodium68$22,959
VyzultaLatanoprostene Bunod51$22,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$48,707$519,344613 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$71$136,876243 claims
AlconSimbrinza, Azopt$48$65,010189 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$19$47,06465 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Besivance, Istalol$31$39,726139 claims
Thea Pharma Inc.Iyuzeh$36$8,22313 claims
NovartisIlevro$283$5,45715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →